SEC Filings

S-1/A
AVEXIS, INC. filed this Form S-1/A on 02/09/2016
Entire Document
 

Table of Contents


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

          This prospectus contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements are contained principally in the sections entitled "Prospectus Summary," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Business" and elsewhere in this prospectus. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions intended to identify statements about the future. These statements speak only as of the date of this prospectus and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward looking statements include, without limitation, statements about the following:

    the timing, progress and results of preclinical studies and clinical trials for AVXS-101 and any other product candidates, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;

    the timing of and our ability to obtain and maintain regulatory approval of AVXS-101;

    our expectations regarding the size of the patient populations for our product candidates, if approved for commercial use;

    our manufacturing capabilities and strategy, including the scalability and commercial viability of our manufacturing methods and processes;

    our ability to successfully commercialize AVXS-101;

    our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing;

    our ability to identify and develop new product candidates;

    our ability to identify, recruit and retain key personnel;

    our and our licensors' ability to protect and enforce our intellectual property protection for AVXS-101, and the scope of such protection;

    our expected use of proceeds from this offering;

    our financial performance;

    the development of and projections relating to our competitors or our industry;

    the impact of laws and regulations;

    our expectations regarding the time during which we will be an emerging growth company under the JOBS Act; and

    the potential purchases by certain of our existing stockholders (and their affiliated entities) in this offering.

          Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not

73



© AveXis, Inc. All Rights Reserved.